Hyperlipidemia primary prevention
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
For patient information click here
Template:DiseaseDisorder infobox
|
Lipoprotein Disorders Microchapters |
Overview
Screening and treatment of lipid disorders in people at high risk for future coronary heart disease (CHD) events has been recommended by the, 'United States Preventive Services Task Force (USPSTF)' especially for patients with known CHD. However, the role of screening in people with low to medium risk is controversial. On the basis of the effectiveness of treatment, the availability of accurate and reliable tests, and the likelihood of identifying people with abnormal lipids and increased CHD risk, screening appears to be effective in middle-aged and older adults and in young adults with additional cardiovascular risk factors.
Primary Prevention
United States Preventive Services Task Force (USPSTF) Screening for Lipid Disorders in Adults [1] (DO NOT EDIT)
| “ |
Screening Men1) The USPSTF strongly recommends screening men aged 35 and older for lipid disorders. (Grade A recommendation) 2) The USPSTF recommends screening men aged 20 to 35 for lipid disorders if they are at increased risk for CHD. (Grade B recommendation) Screening Women at Increased Risk1) The USPSTF strongly recommends screening women aged 45 and older for lipid disorders if they are at increased risk for coronary heart disease. (Grade A recommendation) 2) The USPSTF recommends screening women aged 20 to 45 for lipid disorders if they are at increased risk for CHD. (Grade B recommendation) Screening of Young Men and All Women Not at Increased Risk1) The USPSTF makes no recommendation for or against routine screening for lipid disorders in men aged 20 to 35, or in women aged 20 and older who are not at increased risk for CHD. (Grade C recommendation) Clinical Considerations1) An age to stop screening has not been established. Screening may be appropriate in older people who have never been screened; repeated screening is less important in older people because lipid levels are less likely to increase after age 65. However, because older adults have an increased baseline risk for coronary heart disease, they stand to gain greater absolute benefit from the treatment of dyslipidemia, compared with younger adults.
|
” |